StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) stock

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/302% below fair value
$396.74−1.34 (-0.34%)

Close on Nov 19, 2026Market cap $9.17BP/E –Yield –

Madrigal Pharmaceuticals gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

For fiscal 2024 it was $173.90M.

Annual gross profit

PeriodPeriod endValueChange
FY2024Dec 31, 2024$173.90M–
FY2023Dec 31, 2023$0–
FY2022Dec 31, 2022$0–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2025Mar 31, 2025$132.74M–
Q1 FY2024Mar 31, 2024$0–

More Madrigal Pharmaceuticals figures

See a number that looks wrong?